- Raised funding round led by BIOLIGHT Life Sciences, Dec 2019
About
LipiCare Pharmaceuticals develops products based on nano-emulsions of phospholipids to convey fatty medications to the ocular surface effectively and comfortably. LipiCare is now focused on developing the first commercial product based on this technology, Ocular D, a product for treating dryness in the eye with integrated vitamin D. LipiCare has conducted laboratory testing that has shown that the product helps block blue light radiation and thus may provide additional protection to the eye beyond the existing benefits of the nano-emulsion itself. Development of the product is being carried out by subcontractors, chiefly an Italian manufacturer that produces and markets similar products in Europe. Upon receipt of the marketing approval in Europe for LipiCare's Ocular-D product (CE approval through the medical devices track), LipiCare is expected to commence Ocular-D production and marketing. The company is a subsidiary of Biolight.
Funding history · 1 round · — total
Q&A
- What is LipiCare Pharmaceuticals' primary focus?
- LipiCare Pharmaceuticals develops products based on nano-emulsions of phospholipids to effectively and comfortably deliver fatty medications to the ocular surface. The company is currently focused on Ocular D, a product for treating dry eyes with integrated vitamin D.
- When was LipiCare Pharmaceuticals founded?
- LipiCare Pharmaceuticals was founded in June 2016.
- What is LipiCare Pharmaceuticals' employee count?
- LipiCare Pharmaceuticals has 1-10 employees.
- Which company is LipiCare Pharmaceuticals a subsidiary of?
- LipiCare Pharmaceuticals is a subsidiary of Biolight.
- What is the status of LipiCare Pharmaceuticals' Ocular-D product development?
- Development of Ocular-D is being carried out by subcontractors, primarily an Italian manufacturer. LipiCare expects to commence production and marketing upon receiving CE approval in Europe for the product.
- What is the primary sector of LipiCare Pharmaceuticals?
- LipiCare Pharmaceuticals' primary sector is Health Tech & Life Sciences.
- Has LipiCare Pharmaceuticals secured any funding?
- Yes, LipiCare Pharmaceuticals received funding in December 2019 from BIOLIGHT Life Sciences.
- What additional protection might Ocular D provide?
- Laboratory testing has shown that Ocular D may help block blue light radiation, potentially offering additional protection to the eye beyond the benefits of the nano-emulsion itself.
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | bio-light.co.il/lipicare-2 |
|---|---|
| linkedin.com/company/80939863 |
Identifiers & details
| Founded | 2016-6 |
|---|---|
| Employees (exact) | 1 |
Radar intelligence
Web history (Wayback)
| Domain | bio-light.co.il |
|---|
Certificate / subdomain footprint
| Subdomains | 1 |
|---|